Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies [Yahoo! Finance]
Caris Life Sciences, Inc. (CAI)
Last caris life sciences, inc. earnings: 10/29 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.capps.com/investor-relations
Company Research
Source: Yahoo! Finance
IRVING, Texas April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded. Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences) Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. This fragmented approach can delay c
Show less
Read more
Impact Snapshot
Event Time:
CAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAI alerts
High impacting Caris Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
CAI
News
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies [TheStreet.com]TheStreet.com
- Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid MalignanciesPR Newswire
- Caris Life Sciences (CAI) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating and a $27.00 price target on the stock.MarketBeat
- Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect [Yahoo! Finance]Yahoo! Finance
- Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect [TheStreet.com]TheStreet.com
CAI
Earnings
- 2/26/26 - Beat
CAI
Sec Filings
- 4/2/26 - Form 8-K
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- CAI's page on the SEC website